Keyphrases
Metastatic Pancreatic Ductal Adenocarcinoma
100%
Tumor Immunity
100%
Clinical Benefit Rate
100%
Pembrolizumab
100%
Pelareorep
100%
Non-responders
83%
Tumor
33%
Programmed Death-ligand 1 (PD-L1)
33%
Immunological Changes
33%
Chemotherapy
16%
T Cells
16%
CD8+ T Cells
16%
Antitumor
16%
Overall Response Rate
16%
Stable Disease
16%
T Cell Clone
16%
Immune Markers
16%
Metabolic Biomarkers
16%
Online Treatment
16%
First-line Therapy
16%
Peripheral T Cells
16%
Partial Response
16%
T-cell Clonality
16%
Unselected Patients
16%
CD4+ Tregs
16%
Voltage-dependent Anion Channel 1 (VDAC1)
16%
Soluble PD-L1 (sPD-L1)
16%
Inflamed Tumors
16%
Chemotherapy-free Regimens
16%
Medicine and Dentistry
Pancreas Adenocarcinoma
100%
Tumor Immunity
100%
Pancreatic Ductal Adenocarcinoma
100%
Pelareorep
100%
Pembrolizumab
100%
Neoplasm
80%
T Cell
60%
Programmed Death-Ligand 1
40%
Clonal Variation
20%
Biological Marker
20%
VDAC1
20%
Cytotoxic T-Cell
20%
Diseases
20%
Pharmacology, Toxicology and Pharmaceutical Science
Pancreas Adenocarcinoma
100%
Pembrolizumab
100%
Pelareorep
100%
Neoplasm
100%
Chemotherapy
40%
Biological Marker
20%
CD8 Antigen
20%
Diseases
20%
Immunology and Microbiology
Pembrolizumab
100%
Tumor Immunity
100%
Pelareorep
100%
T Cell
60%
Programmed Death-Ligand 1
40%
Regulatory T Cell
20%
Cytotoxic T-Cell
20%
CD4
20%
Cell Clone
20%
Clonal Variation
20%